Nav: Home

Percutaneous ablation vs. surgery for hepatocellular carcinoma

May 07, 2019

Leesburg, VA, May 7, 2019--Compared to surgery, percutaneous liver ablation interventions (IRs) in patients with hepatocellular carcinoma (HCC) are associated with lower inhospital mortality, length of hospital stay (LOS), and hospitalization costs, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

The study was conducted to compare use rates and outcomes of locoregional liver interventions IRs for HCC with surgical procedures.

A total of 557,071 hospitalizations in patients with HCC from 2002 to 2015 were extracted from the National Inpatient Sample database, with an estimated 13,618 IRs and 44,629 surgical procedures performed. Hospitalizations with coexisting diagnoses of secondary hepatic and primary biliary malignancies, neuroendocrine tumors and benign hepatobiliary neoplasms, and traumatic liver injuries were excluded from the study.

Over the 14-year period, unadjusted inhospital mortality rate, LOS, and hospitalization costs were higher for surgical procedures, and after adjusting for comorbidity score, year, and patient- and hospital-specific factors, results showed IR was associated with 78% lower inhospital mortality, 37% higher routine discharge to home, 67% lower LOS, and 71% lower cost.
-end-
With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

American Roentgen Ray Society

Related Hepatocellular Carcinoma Articles:

Dogs help in breast carcinoma research
Cancer of the mammary glands in dogs is very similar to human breast carcinoma.
Crizotinib in bronchial carcinoma: New data not informative
After expiry of the limitation period, the manufacturer presented results from a later data cut-off.
Sorafenib treatment alters immunosuppressive phenotypes in hepatocellular carcinoma
In this issue of JCI Insight, Yasmin Thanavala and colleagues at Roswell Park Cancer Institute evaluated the immune response in a small cohort of patients with advanced hepatocellular carcinoma before and after treatment with sorafenib.
Identifying how Merkel cell polyomavirus infection can cause a lethal carcinoma
A benign virus normally found in the skin can lead to a type of rare, lethal skin cancer.
Vismodegib in basal cell carcinoma: Added benefit not proven
The drug manufacturer presented no suitable data after expiry of the limitation period.
Study shows possible 'key' to improved therapy for adrenocortical carcinoma
A study comprised of 39 international institutions revealed significant new findings about adrenocortical carcinoma, a rare cancer with an often poor prognosis.
New hepatocellular carcinoma prognostic model improves prediction of patient survival
The ITA.LI.CA prognostic system, a model integrating tumor staging, liver function, functional status, and alpha-fetoprotein level, builds on previous models of hepatocellular carcinoma (HCC) prognosis and shows superior survival prediction in Italian and Taiwanese cohorts, according to a study published this week in PLOS Medicine by Alessandro Vitale of Azienda Ospedaliera Universitaria di Padova, Italy, and colleagues.
Merkel cell carcinoma patients who received pembrolizumab often had durable responses
In a phase 2 clinical trial of the immunotherapy drug pembrolizumab as a first-line systemic therapy for advanced Merkel cell carcinoma, or MCC -- a rare, aggressive type of skin cancer -- the clinical response rate was similar to that typically seen with standard chemotherapy, but the duration of the response appeared to be markedly longer.
Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven
In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive.
Towards the goal of precision therapy in hepatocellular carcinoma
Hepatocellular carcinoma is a highly lethal disease, therefore effective and tolerable treatment is urgently needed.

Related Hepatocellular Carcinoma Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...